Homepage > Company > Media > Pharma News > 2025 > Avenacy intros generic Zometa

Avenacy intros generic Zometa

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, has launched zoledronic acid injection, which is a generic of Novartis’ Zometa.

Zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy and for the treatment of multiple myeloma and bone metastases of solid tumors, in conjunction with standard antineoplastic therapy. Avenacy's zoledronic acid injection is available as a 4 mg/5 ml (0.8 mg per ml) single-dose vial.

Avenacy said that the medication will feature the company’s highly differentiated packaging and labeling to support accurate medication selection.

Zoledronic acid injection had a market value of approximately $11.4 million for the 12 months ending in September 2024, per IQVIA.

Avenacy is a rapidly growing U.S.-based specialty pharmaceutical company focused on providing critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential injectable medications.

Read also

UK and US agree on landmark pharma pricing tariff deal

The UK and US have agreed to keep tariffs on UK pharmaceutical shipments into the US at zero.

Parkinson's drug as basis for new anti-infectives

Pseudomonas aeruginosa – one of the most common hospital germs – has sophisticated mechanisms to efficiently infect the human body and evade the immune system or antibiotics.

Modified herpes virus helps destroy glioblastoma in preclinical models

Researchers at Mass General Brigham have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells.

Curi Bio: $10 Million Series B Closed To Scale Human-Relevant Preclinical Platforms

Curi Bio has secured a $10 million Series B round led by Seoul-based contract research organization DreamCIS, funding that will accelerate the expansion of the company’s integrated human-relevant pr...